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Introduction
Contemporary model of the pathogenesis of atheroscle-
rosis is based on the hypothesis that local damage of the en-
dothelium together with systemic factors such as hypercho-
lesterolemia, hyperglycemia, hypertension, chronically in-
fections, genetic factors, diabetes mellitus, initiate a cascade
of processes which eventually cause atherosclerotic lesion
development
 1, 2.
Although various hypotheses are already known about
the pathogenesis of atherosclerosis and different factors of
predisposition have been studied, from the point of molecu-
lar and vascular biology to clinical presentations and therapy
methods, in modern literature there are still opposing views
about the initial moment in the pathogenesis of this condi-
tion, regarding its functional and morphological changes.
The stage of the initial lesion - early lesion (type I)
Activation of endothelium
The initial stage, which precedes the development of ath-
erosclerosis, is endothelial dysfunction, namely, activation of
endothelial cells as a specific response to the action of harmful
agents. Acute response of endothelium results in inflamma-
tion, coagulation disorders and vasomotor changes. The re-
lease of inflammation mediators deposited in the Weibel
Palade bodies represents a very quick response of endothelial
cells
 3. One of the most important consequences of endothelial
activation is a decreased NO production, which causes the ab-
sence of its antiatherogenic, antiproliferative and vasodilata-
tory effects and, also, causes an increased production of en-
dothelin-1 (ET-1) which in turn, through its mitogenic effect,
stimulates proliferation of smooth muscle cells (SMCs) in the
intima, and consequently initiate atherosclerosis
 4, 5.
During activation of endothelial cells, changes in the
process of coagulation have also been observed. Endothelial
cells modulate their phenotype from anticoagulative to pro-
coagulative, through an increased expression of tissue fac-
tors, or increased release of tissue plasminogen
 6, 7.
Besides alterations in tonus and coagulation, endothelial
activation includes increased expression of adhesive proteins
(P-selectin, integrins) which promote the adhesion of leuko-
cytes on endothelium and their infiltration in the subendo-
thelial connective tissue
 8. This results in the release of free
radicals, proteases and elastases which lead to further dam-
age of endothelial cells
 7.
Accumulation of lipids in the intima
The first step in the development of atherosclerosis is
the accumulation of lipid droplets in the intima of the vesselStrana 1008 VOJNOSANITETSKI PREGLED Volumen 67, Broj 12
Vuković I, et al. Vojnosanit Pregl 2010; 67(12): 1007–1014.
wall, as a consequence of hypercholesterolemia, coupled
with systemic hypertension. Lipid droplets bind to proteo-
glycans in the intimal connective tissue and have a tendency
to form aggregates
 9. Lipoproteins in the lipid droplets may
oxidize or become chemically modified in other ways
 10, 11.
Hypothesis of oxidative modification
Oxidative modification is the best researched study
about the modification of lipoproteins (LDL) in atherosclero-
sis. Studies showed that oxidized LDL (ox-LDL) has been
intensely absorbed in the culture of macrophages, partially
through SR-A receptor, but in a larger part through other
scavenger receptors, especially CD36. Circulating mono-
cytes express SR-A and CD36, but at a lower degree. How-
ever, when monocyte enters into vascular wall and trans-
forms to macrophage, during this transformation the expres-
sion of scavenger receptors is increased, and this allows ab-
sorption of modified LDL forms 
12.
The rate of production of ox-LDL in the arterial intima
is related to the concentration of native LDL. Concentration
of native LDL in the intima depends on its concentration in
plasma. These results have shown that possible predilected
places for pathogenesis of atherosclerotic lesions could be
thickenings of the intima on the proximal parts of the artery,
after their branching or bifurcation
 13.
Furthermore, it has been experimentally approved that
the concentration of LDL in the vascular intima is higher in
places where atherosclerosis will develop, compared to the
places which are resistant
 14. It is interesting that permeability
of the overlying endothelium is not increased, which means
that LDL somehow selectively accumulates in those places.
It is proven that LDL in these predilection places binds to
proteoglycans of extracellular matrix
 9. Lipid droplets binded
to proteoglycans in this way oxidize much more easily
 15–17.
Also according to the literature, genetically engineered LDL
does not bind to proteoglycans, which means it is less patho-
genic than native LDL
 18. The presence of SMCs of synthetic
phenotype contributes to the accumulation of LDL in intima.
The number of these cells is increased in initial lesions; they
act as fibroblasts and synthesize large amounts of proteogly-
cans.  Previously presented facts suggest that the accumula-
tion of LDL in intima could be the initial step in the patho-
genesis of atherosclerotic lesion
 16, 17.
At the initial lesions beside the increased expression of
the vascular cell adhesion molecule-1 (VCAM-1), which se-
lectively promotes the adhesion of lymphocytes and mono-
cytes, ox-LDL itself contributes to the adhesion of these cells
on the endothelial layer 
18. Oxidized LDL has cytotoxic ef-
fect on endothelial cells, acts as a mitogen of macrophages
and SMCs and stimulates the release of monocyte chemoat-
tractant protein-1 (MCP-1) and monocyte colony-stimulated
factor (M-CSF) from endothelial cells, which directly starts
chemotaxis and migration of monocytes into the subendo-
thelial layer 
19.
Degradation of polyunsaturated fatty acids in sn-2 place
of phospholipids in LDL generates ox-LDL. After genera-
tion, ox-LDL binds to proteoglycans and becomes uptaken
by macrophages through scavenger receptors
 20.
Expression of adhesion molecules in atherosclerosis
After initiation by hypercholesterolemia, leukocytes (at
first, monocytes and T lymphocytes) adhere to the endothe-
lium and actively migrate both, between and through endo-
thelial cells into the intima
 21. In the subendothelium of the
intima monocytes begin to accumulate lipids and begin trans-
forming into foam cells. In that manner, increased expression
of adhesion molecules, as a consequence of endothelial dys-
function and the accumulation of lipid droplets in the intima,
promote adhesion of leukocytes to the endothelial layer and
their migration into the subendothelium, in the initial and ad-
vanced stages of atherosclerosis
 22–24.
A variety of adhesion molecules have been identified as
important for this process. These include immunoglobulin
superfamily members intercellular adhesion molecules 1 and
2 (ICAM-1 and ICAM-2), vascular cell adhesion molecule 1
(VCAM-1), platelet-endothelial cell adhesion molecule-1
(PECAM-1), as well as E-, P- and L-selectin
 21, 25, 26.
Increased expression of VCAM-1 is a characteristic of
an initial stage of atherosclerosis. This molecule interacts
with specific integrin, very late antigen-4 (VLA-4), which is
expressed only on monocytes and lymphocytes
 25, 27. As a re-
sult of this fact, at the initial stage of atherosclerosis, mono-
cytes and T cells adhere in a significantly higher percentage
than other types of leukocytes
 28, 29. On the other hand,
ICAM-1 allows adhesion of a number of different leuko-
cytes, because it interacts with CD11a (LFA-1) and CD11b
(Mac-1) integrins on their membranes, and its expression is a
characteristic of advanced atherosclerotic lesions
 25, 27.
E-selectin (previously ELAM-1) is a typical represen-
tative of this group of adhesion molecules. Its name derives
from a specific expression only on endothelial cells. Its in-
creased expression is a characteristic of the advanced athero-
sclerotic lesions. This molecule interacts with Sialyl-Lewis X
ligand on the membrane of granulocytes and memory T cells
and due to this fact, at the advanced atherosclerotic lesions,
these cells adhere to endothelial layer in a significantly
higher percentage
 25, 27.
P-selectin (previously GMP-140) is expressed primarily
in thrombocytes, but also in overlying endothelium above
atherosclerotic lesions. This molecule interacts with P–se-
lectin glycoprotein ligand-1 (PSGL-1) on monocytes, lym-
phocytes and granulocytes. It has a significant role in „roll-
ing“ of leukocytes on endothelial layer above the lesion
 30–32.
L-selectin is expressed on leukocytes and interacts with
PSGL-1 ligand on monocytes, lymphocytes and granulo-
cytes, but also with mucosal vascular addressin cell adhesion
molecular link-1 (MAdCAM-1)
 25, 27, 31.
In the endothelium above an atherosclerotic plaque, in
the sites of infiltration of macrophages, there is a noticeable
increase of expression of ICAM-1 and P-selectin
 21, 23, 30.
These results indicate that the accumulation of monocytes
which will later transform into macrophages partially depen-
des on synergic action of P-selectin and ICAM-1 on the en-
dothelial layer
 31, 32.
Many factors combined can induce an expression of
endothelial adhesion molecules in atherosclerosis
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factors are ox-LDL, inflammatory cytokines and biome-
chanical strength of blood shear stress. In the tissue culture,
it is noticeable that the treatment of endothelial cells with ox-
LDL increases the expression of P-selectin, ICAM-1 and
VCAM-1
 32, 33. Cytokines, including interleukin-1 (IL-1) and
tumor necrosis factor-α (TNF-α), increase the infiltration of
leukocytes through adhesion molecules
 2. Regarding biome-
chanical stimuli, it is shown that the regulation of ICAM-1
expression is under influence of blood flow
 34.
Migration of leukocytes through endothelial layer
When leukocytes adhere to endothelium, they must re-
ceive a signal in order to go through endothelium into the
deeper layers of vascular wall. Two characteristic processes,
selectin-mediated rolling and integrin-mediated adhesion,
cooperate to promote active migration of leukocytes, both
across endothelial cells (transendothelial migration) and by
diapedesis. Rolling of leukocytes and migration into the vas-
cular wall are the crucial first steps in the development of in-
flammation and atherosclerosis
 21.
Contemporary concepts regarding direct migration of
leukocytes include activation of special cytokines-chemokines.
At the early stage of atherosclerosis, one of those cytokines,
MCP-1 is being produced in the endothelial cells, as a re-
sponse to ox-LDL and other stimuli
 34, 35. This cytokine di-
rectly starts chemotaxis and the migration of monocytes into
the subendothelial layer. At this stage, subpopulations of inti-
mal SMCs and endothelial cells also express M-CSF which
also promotes chemotaxis of monocytes, their adhesion and
differentiation to macrophages, regulate proliferation of
macrophages and other types of cells, which is implicated in
inflammatory-fibroproliferative response at the advanced
stages of atherosclerosis. Oxidized LDL also stimulates endo-
thelial cells to express granulocyte colony-stimulating factor
(G-CSF) and granulocyte-macrophage colony-stimulating
factor (GM-CSF). These growth factors affect differentiation,
survival, proliferation, migration and metabolism of macro-
phages/granulocytes, and G–CSF and GM–CSF also affect
migration and proliferation of endothelial cells 
32–35.
Other types of chemokines may also increase lympho-
cyte accumulation in plaque. In atherosclerotic lesion, over-
lying endothelium expresses three types of lymphocyte-
selective chemokines: interferon-inducible protein-10 (IP-
10), interferon-inducible T-cell alpha chemoattractant (I-
TAC) and monokine induced by interferon-γ (MIG). Inter-
feron-γ which is present in the atherosclerotic lesion induces
genes which code T cell hemoattractant protein family of
chemokine, and subsequently, accumulation of T cells in
plaque
 36, 37.
Foam cells of monocyte-macrophage lineage
When monocytes enter the intima of a vessel wall, they
undergo phenotype modification to macrophages. Macro-
phages then accumulate lipid droplets and become foam
cells. The mechanism of cholesterol uptaking in macro-
phages is especially interesting.
Most of the cells use a plasma membrane receptor to
uptake and release cholesterol. When a cell uptakes choles-
terol for its own metabolic needs, a mechanism of the tran-
scription control of this receptor become activated, which in
turn shuts down the receptor expression and completely shuts
down further absorption of cholesterol. On the contrary,
macrophages in the atherosclerotic lesion (future foam cells)
do not posses this kind of negative feedback, so it is obvious
that they uptake cholesterol through some other kind of re-
ceptors
 38.
Some investigations have shown that in the culture of
macrophages in in vitro conditions, cells rapidly uptake
modified, acetylated LDL, not through the known LDL re-
ceptor, but through the special “acetyl-LDL” receptor. Later,
this receptor is cloned and called the scavenger receptor A
(SR-A). Contrary to LDL receptor, expression of SR-A is not
down-regulated as a response to the increased intracellular
concentration of cholesterol. Theoretically, this kind of re-
ceptor might have a role in forming foam cells, because there
is no data that acetyl-LDL has been generated in in vivo con-
ditions
 39, 40. According to literature, the various modified
forms of LDL also could have a role in the creation of foam
cells, which brings out the question of the existence of vari-
ous receptors
 41, 42.
Other studies
 42–44 have shown that some foam cells
originate from SMCs, probably due to the fact that SMCs
can also express scavenger receptors if they are properly ac-
tivated, which will be discussed later.
Cytohistological characteristics of an initial lesion –
early lesion (type I)
The results of a large number of recent studies on cyto-
histological characteristics of atherosclerotic lesions have
shown that at the stage of initial lesion (early lesion – type I)
there are no visible morphological changes in the structure of
vascular wall, which is in accordance with the previously
stated pathogenic mechanisms. According to these results, at
the initial stage endothelial continuity is preserved, with the
presence of individual foam cells and T cells in the intima.
At initial phases of lesions circulating monocytes are the
main precursors to foam cells. Smooth muscle cells in the
intima and media show contractile phenotype (Figure 1).
Their phenotype modulation from the contractile to synthetic
phenotype can be noticed during the fatty streak stage 
28, 45, 46.
The fatty streak stage - early lesion (type II)
Cytohistological characteristics of the fatty streak stage
– early lesion (type II)
With further development of atherosclerotic lesion, at
the fatty streak stage (early lesion – type II) increase in the
number of foam cells (Figure 2) and intense infiltration of T
cells occurs. At this stage, lipid accumulation in foam cells
forms fatty streaks. Endothelial layer is still morphologically
preserved, although it is functionally damaged
 46, 47.
Foam cells at this stage originate from macrophages
(Figure 3)
 46, 47. The fatty streak stage is also characterized by
the presence of SMCs of synthetic phenotype, but they are
not foam cells yet 
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Fig. 1 – Coronary atherosclerosis at the initial stage.
Endothelial layer is well-preserved without visible
morphological changes. Smooth muscle cells in intima and
media show contractyle phenotype (immunohistochemical
staining of MHC, original magnification ×64)
Fig. 2 – Coronary atherosclerosis at the fatty streak stage.
Foam cells in subendothelial layer (immunohistochemical
staining of CD68, original magnification ×256)
Fig. 3 – Coronary atherosclerosis at the fatty streak stage.
Macrophage with a large number of lipid inclusions in cyto-
plasm, ie foam cell that originate from the monocyte-
macrophage lineage (TEM, original magnification ×16875)
Smooth muscle cells (SMCs)
The results of testing phenotypical status of SMCs of
atherosclerotic lesions showed that from a fatty streak stage,
the modified SMCs of synthetic phenotype form the domi-
nant cell population
 28. The development of synthetic phe-
notype is followed by a reduction in myofilaments 
29.
Smooth muscle cells of synthetic phenotype expressed α-
smooth muscle actin (α-SMA) and vimentin, with a lack of
expression of desmin
 43, 48. The loss of desmin expression
with concurrent vimentin expression is the first sign in the
process of switching from contractile to synthetic pheno-
type
 43, 49. According to the existing literature, vimentin is an
intermediary filament that can be found in differentiated
SMCs as well, but it is coexpressed there with desmin. With
the loss of contractile phenotype and characteristic desmin
expression (i.e. with switching of cells to synthetic pheno-
type), the expression of vimentin filaments can be no-
ticed
 28, 45, 50.
Switching of SMCs to synthetic phenotype is a main
characteristic of vascular remodeling during the pathogenesis
of atherosclerosis 
48, 51. Vascular remodeling is an adaptive
process involving the adjustment of structure and function of
blood vessels to long-term changes in hemodynamic condi-
tions, especially to hypertension
 45, 52. Scientific reports prove
that reactive – adaptive intimal proliferation (“early re-
sponse” of the wall) during the process of vascular remodel-
ing, does not have a mechanism of negative feedback and
that it can be continued in the form of intimal hyperplasia. In
the primary response to the conditions of increased pressure,
there is a proliferation of endothelial cells in vascular wall.
After endothelial proliferation, during a rather long period of
time it is characterized by SMCs proliferation accompanied
by vascular wall thickening. The increased synthesis of col-
lagen and elastin, which is an alteration of gene expression
for the synthesis of these proteins, is the explanation for
rapid enlargement and irreversible thickening in atheroscle-
rotic vascular remodeling, in spite of apoptosis which is acti-
vated after proliferation of SMCs
 52, 53.
Under the influence of chemotactic factors, SMCs mi-
grate through fenestrae of the internal elastic lamina. As they
express specific integrins (α2β1 which binds collagen and
α3β1 and α5β1 which bind fibronectin) and elastin binding
proteins on plasma membrane, they come in contact with con-
nective tissue components and start to proliferate as a response
to the stimuli of platelet-derived growth factor (PDGF) and fi-
broblast growth factors (FGFs)
 55. At the same time, under the
influence of TGF-β, SMCs begin to secrete extracellular ma-
trix components, thereby increasing the amount of collagen IV
and collagen V. These changes were associated with up regu-
lation of transforming growth factor β (TGF- β)
 52.
Also, at this stage, adventitial myofibroblasts start to
show the characteristics of contractile SMCs
 29, 47, 48. Ac-
cording to the same data, the increased expression of TGF-β
in adventitia is the signal for differentiation of fibroblasts
(which start to express α-SMA and the other markers of
SMCs differentiation as well) and their migration, which
makes it hard to differentiate from medial SMCs (Figure 4).Volumen 67, Broj 12 VOJNOSANITETSKI PREGLED Strana 1011
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Fig. 4 – Coronary atherosclerosis at the fatty streak stage.
Myofibroblasts in adventitia start to show the characteristics
of contractile smooth muscle cells (immunohistochemical
staining of MHC, original magnification ×64)
A number of important stimulators and inhibitors of both
SMCs and endothelial cells in atherosclerotic lesions have
now been purified and biochemically characterized. Included
in the group of stimulators are FGFs, vascular endothelial
growth factor (VEGF), PDGF, epidermal growth factor (EGF)
like factors, angiogenin, also vasoconstrictor peptides (which
induce proliferation of SMCs and the expression of TGF-β and
PDGF), angiotensin converting enzyme (ACE) (which induces
proliferation of SMCs in in vivo conditions), insulin-like
growth factors (IGFs) (potential mitogen of SMCs), interleu-
kin-1 (IL1) (induces expression of FGF in SMCs), lipoprotein
A (stimulates proliferation of SMCs) and ET-1
 22, 54.
Bifunctional growth factors, TGF-β and TNF-α, also
have an influence on the proliferation and migration of
SMCs. A multifunctional cytokine is TGF-β, which in its in-
active form is being synthesized by endothelial cells and
SMCs. This cytokine becomes activated under the influence
of plasmin and induces differentiation of endothelial cells
and SMCs, but paradoxically inhibits their migration and
proliferation. TNF-α is cytokine which inhibits proliferation
of endothelial cells and SMCs but it stimulates the transcrip-
tion of heparin-binding EGF-like growth factor (HB-EGF) in
SMCs
 31, 54. Each of these factors may influence the growth
of SMCs or endothelial cell, both as a stimulant or inhibitor.
The preatheroma stage – intermediary lesion (type III)
Cytohistological characteristics of the preatheroma
stage – intermediary lesion (typeIII)
At the preatheroma stage – intermediary lesion (type III),
lipid accumulation surpasses the accumulation by foam cells
and subendothelial layer contain scattered collections of extra-
cellular lipid droplets and particles in the form of small iso-
lated pools of extracellular lipid. The preatheroma stage is
characterized by the presence of intimal and medial prolifer-
ating SMCs of synthetic phenotype (Figure 5). The phenotype
modulation of intimal and medial SMCs (based on the loss of
desmin expression and the appearance of vimentin expression)
begins at the fatty streak stage, and at the preatheroma stage
these cells form the dominant cell population
 28, 29, 45.
Fig. 5 – Coronary atherosclerosis at the preatheroma stage.
Smooth muscle cells of the synthetic phenotype
(immunohistochemical staining of vimentin, original
magnification ×128)
The intermediary lesion is also characterized by a large
number of foam cells of various origin. Some of foam cells
develop from monocyte-macrophage lineage (the same as at
the fatty streak stage) and others originate from
SMCs
 28, 46, 47. Foam cells that originate from SMCs are spin-
dle-shaped or star-shaped and they have short, thick exten-
sions with lipid inclusions in cytoplasm (Figure 6)
 28, 48.
Fig. 6 – Coronary atherosclerosis at the preatheroma stage.
We can notice the presence of foam cells that originate from
smooth muscle cells. These lipid-laden smooth muscle cells are
spindle-shaped or star-shaped, with lipid inclusions in the cy-
toplasm and they have short, thick extensions. The number of
lipid inclusions in the cells varies, and therefore, they look as if
they are at the different stages of phenotype transformations
to foam cells (TEM, original magnification ×8250)
Foam cells of smooth muscle cells origin
The results of many studies have shown that SMCs of
synthetic phenotype, proliferate and start to accumulate lip-
ids from the fatty streak stage, but their largest number can
be observed at the preatheroma stage
 28, 29, 45. According to
the same data, some foam cells in atherosclerosis originate
from SMCs of synthetic phenotype (express vimentin-
immunoreactivity), probably due to the fact that some SMCs
can also express scavenger receptors. Vimentin-immuno-Strana 1012 VOJNOSANITETSKI PREGLED Volumen 67, Broj 12
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reactivity points out to their syntetic/proliferative activity
and also to their mesenchymal origin
 45, 46.
The fact that SMCs express scavenger receptors and
modulate to foam cells is possibly related to the embryonic
origin of vascular SMCs
 44. All vascular SMCs have a mes-
enchymal origin, except for the fact that large arteries in the
upper parts of the body can have the neuroectodermal ori-
gin
 28, 56, 57. Due to their mesenchymal origin, SMCs coex-
press vimentin and desmin. During remodeling of vascular
wall in atherosclerosis, there is a loss of contractile charac-
teristics of SMCs and characteristic desmin expression so
that SMCs of the synthetic phenotype express only
vimentin
 28, 29, 43. After loss of contractile characteristics,
SMCs proliferate and as a result of this proliferation start to
intensively express S-100 protein. For both, SMCs of mesen-
chymal origin, as well as for SMCs of neuroectodermal ori-
gin, expression of this protein is a normal characteristic, but
it is increased in processes which are Ca
++ – mediated. This
protein in increased expression shows a high affinity to bind
unsaturated lipid acids
 58. It has been assumed that SMCs due
to their synthetic and proliferative activity can accumulate
lipids.
Pathogenesis of atherosclerosis as an inflammatory
response of vascular wall
Earlier theories about the pathogenesis of atherosclero-
sis have assumed hypercholesterolemia as a necessary con-
dition for the development of this disease. Only in the later
decades, numerous researches have pointed out to inflamma-
tion as a basis for pathogenesis of atherosclerosis
 27.
As mentioned above, beginning with the initial le-
sion stage, in the response to the presence of modified
lipids in the subendothelial layer, endothelial cells in-
crease the expression of adhesion molecules, at first
VCAM-1, which selectively promotes the adhesion of
monocytes and T cells on endothelial layer. In response to
the same stimulus endothelial cells express monocyte-
selective chemokine MCP-1 and three types of lympho-
cyte-selective chemokines (IP-10, I-TAC and MIG) which
directly start chemotaxis and migration of monocytes and
T cells into the subendothelial layer. The presence of
macrophages and T cells in subendothelial layer show that
the early stages of atherosclerotic lesion are an inflam-
matory response to exogenous pathogens 
27, 51.
However, in addition to modified lipids, other exoge-
nous pathogens, especially microorganisms, also promote in-
flammation. These antigens become presented by antigen-
presenting cells (APCs), to Th CD4+ cells trough the MHC
class II-dependent pathway. In response to immunological
activation, mature forms of Th CD4+ cells begin to produce
proinflammatory cytokines IL-2, IFN-γ and TNF-β. These
cells also interreact with Tc CD8+ cells, NKT cells and
macrophages, helping them to finish a started immune re-
sponse against intracellural pathogens 
27.
The role of APCs during atherosclerosis is played by
macrophages, vascular dendritic cells (VDCs) and B cells, as
a “professional APCs”, but recent studies have show that low
differentiated forms of SMCs also can process and present
antigens
 59, 60. All APCs in vascular wall internalize antigens
either by phagocytosis or by receptor-mediated endocytosis,
and display a fragment of antigen bound to the class II MHC
molecule on their plasma membrane. Expression of the anti-
gen-class II MHC molecule complex which is a ligand for a
T-cell receptor (TCR), on the membranes of APCs with ad-
ditional co-stimulatory signals from APCs leads to immu-
nological activation of T cells and manifestation of inflam-
matory reactions
 27, 59, 60.
A great number of recent studies aimed to improve
therapeutic procedures have been focused on the role of IFN-
γ during atherosclerosis. Immediately after entrance into a
subendothelial layer, T cells produce IFN-γ which induces
genes that code T cell hemoattractant protein family of che-
mokine, and subsequently, further accumulation of T cells in
the plaque. Besides, this cytokine activates macrophages
immunoregulatory functions and simultaneously affects
SMCs of a lesion. These literature data support the hypothe-
sis that IFN-γ is a potent atherogenic cytokine, which signifi-
cantly increases both, lesion size as well as the number of T
lymphocytes within lesions, and also up regulates PDGF
which causes an increased migration of smooth muscle
cells
 60, 61.
If pathogenesis of atherosclerosis is viewed, in the light
of these previously stated facts, as an inflammation, it can be
concluded that during the early stages, atherosclerosis, as a
specialized form of inflammation, responds to an injury of
vascular wall and the presence of different pathogens
 51. With
further progression of inflammatory reaction, during the
stages of advanced atherosclerotic lesions, development of a
chronic inflammatory fibroproliferative response occurs,
which is histologically manifested as atheroma (type IV), le-
sion with a lipid core; fibroatheroma (type V), lesion with a
lipid core and prominent fibrous connective tissue above it,
or complicated atherosclerotic lesion that is defined as type
IV or V lesions with disruptions of lesion surface, hematoma
or hemorrhage, and developed thrombotic deposits (Figures
7 and 8)
 28, 45, 46, 48.
Fig. 7 – Advanced atherosclerotic lesion in the coronary
artery – complicated, ulcerated atherosclerotic plaque with
intraplaque hemorrhage (histochemical staining of Azzan-
Heidenhain, original magnification ×32)Volumen 67, Broj 12 VOJNOSANITETSKI PREGLED Strana 1013
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Fig. 8 – Advanced atherosclerotic lesion in the coronary
artery – complicated atherosclerotic plaque with atheroma,
fibroatheroma, fissure, intraplaque hemorrhage and
thrombus (histochemical staining of Azzan-Heidenhain,
original magnification ×8)
Conclusion
From all the previously presented facts we can conclude
that the basic predisposing factor for development of athero-
sclerosis is hypercholesterolemia or infection, coupled with
systemic hypertension.
The increased levels of plasma cholesterol promote the
entrance of lipid droplets in subendothelial layer, their bind-
ing to proteoglycans and modification of LDL. Modified
LDL stimulates increased expression of adhesion molecules
and promotes the adhesion of leukocytes. Modified LDL also
stimulates the production of cytokines-chemokines in endo-
thelial cells which promotes the migration of leukocytes into
the subendothelial layer, and also initiates synthesis of
growth factors which affect differentiation, modulation, mi-
gration and proliferation of different cell types in the lesion.
From the above presented facts we can conclude, too, that
hypercholesterolemia starts circulus vitiosus in which many
combined factors induce the development of inflammation in
atherosclerosis. In addition to modified forms of LDL, the
presence of other exogenous pathogens (especially microor-
ganisms) initiates atherosclerosis through inflammatory re-
sponse of vascular wall.
On the other hand, systemic hypertension promotes
vascular remodeling. This process is characterized by smooth
muscle cells phenotype modulation from contractile to syn-
thetic phenotype, their migration from media into the suben-
dothelial layer, their proliferation and collagen synthesis, as
well as their transformation to foam cells in the presence of
modified LDL, inflammatory cytokines and biomechanical
strength of blood shear stress.
The previously analyzed facts suggest that atherosclero-
sis could be defined as inflammation which is a response to
hypercholesterolemia or other exogenous pathogens, coupled
with vascular remodeling, caused by systemic hypertension.
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